Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives - PubMed (original) (raw)

Review

doi: 10.1038/nrd3115.

Richard Frank, Karl Broich, Stefan J Teipel, Russell G Katz, John Hardy, Karl Herholz, Arun L W Bokde, Frank Jessen, Yvonne C Hoessler, Wendy R Sanhai, Henrik Zetterberg, Janet Woodcock, Kaj Blennow

Affiliations

Review

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives

Harald Hampel et al. Nat Rev Drug Discov. 2010 Jul.

Abstract

Advances in therapeutic strategies for Alzheimer's disease that lead to even small delays in onset and progression of the condition would significantly reduce the global burden of the disease. To effectively test compounds for Alzheimer's disease and bring therapy to individuals as early as possible there is an urgent need for collaboration between academic institutions, industry and regulatory organizations for the establishment of standards and networks for the identification and qualification of biological marker candidates. Biomarkers are needed to monitor drug safety, to identify individuals who are most likely to respond to specific treatments, to stratify presymptomatic patients and to quantify the benefits of treatments. Biomarkers that achieve these characteristics should enable objective business decisions in portfolio management and facilitate regulatory approval of new therapies.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Neurology. 2005 May 10;64(9):1553-62 - PubMed
    1. Brain. 2006 Nov;129(Pt 11):3035-41 - PubMed
    1. J Pharmacol Exp Ther. 2009 Jan;328(1):131-40 - PubMed
    1. Lancet Neurol. 2008 Feb;7(2):129-35 - PubMed
    1. Lancet Neurol. 2009 Jul;8(7):619-27 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources